Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 648 is a nuclear DNA-binding transcription factor characterized by a C-terminal domain containing tandem C2H2 zinc fingers, with at least six highly conserved across vertebrate evolution[1][2]. It lacks the typical KRAB, BTB/POZ, or SCAN domains common in other zinc finger proteins and shows exclusive nuclear localization[2][3]. ZNF648 is specifically required for erythroid and megakaryocyte differentiation, with loss leading to disrupted cell lineage commitment and cell death[1][2]. Expression is highest in megakaryocytes, but also found in erythroid cells, hematopoietic stem cells, monocytes, CD8+ T cells, and some non-hematopoietic tissues[2]. The gene is conserved across vertebrates from bony fish to mammals, and its molecular architecture facilitates high-affinity DNA binding, likely regulating specific transcriptional programs in blood cell development[1][2][4]. Its broader cellular expression suggests additional regulatory roles beyond hematopoiesis, but no drugs are known to target this factor and it is not established as a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 648 (ZNF648).